Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.70 |
| ▸ | RELA | Q04206 | 1/20 | 0.70 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.68 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6526030 | 1.00 | MAPT (0.70) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6097507 | 0.88 | MEN1 (0.75) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8064094 | 0.86 | MEN1 (0.61) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8048921 | 0.86 | MEN1 (0.61) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8048925 | 0.86 | MEN1 (0.61) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL28947487 | 0.86 | TRPM2 (0.67) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL28947486 | 0.86 | TRPM2 (0.67) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8064096 | 0.86 | MEN1 (0.61) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8635718 | 0.83 | TRPA1 (0.78) | MAPTMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8635715 | 0.83 | TRPA1 (0.78) | MAPTMEN1KMT2ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | claimed |
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | disclosed |
| US-6127392-A | A MUSCLE RELAXANT FOR TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION VIA POTASSIUM CHANNEL AND CHLORIDE CHANNEL MODULATION; INOTROPIC AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-6046239-A | USED IN THE TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION, VIA POTASSIUM CHANNEL AND CHLORIDE CHANNEL MODULATION SUCH AS URINARY INCONTINENCE, ASTHMA, ANGINA, PREMATURE LABOR, CONGESTIVE HEART FAILURE | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | NAAA, ELANE, APEH | MAPT 3467/4885MEN1 3484/4885KMT2A 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.